RxDoctor Payments DataLook up a doctor →

Jeffrey Tyler, MD

Interventional Cardiology · Orange, CANPI 1588082820

Payments from drug & device makers

$411,116in general payments, 2019–2025

Across 803 payments — averaging $511.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$167K
  • Abiomed$105K
  • Edwards Lifesciences$25K
  • Abbott$22K
  • Cardiovascular Systems Inc.$20K
  • Lilly USA, LLC$18K
  • plus $54K from 36 others
$30in research payments, 2019–2025

Across 1 payment — averaging $30.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$30

What the payments were for

  • Consulting fees$83,67320%
  • Speaking & faculty fees$223,35454%
  • Grants$15,0004%
  • Travel & lodging$55,44913%
  • Food & beverage$33,0898%
  • Education$2700%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$411,116 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$906,408
Medicare patients
522
Services billed
3,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$224,377
JardianceEmpagliflozin108$148,708
EntrestoSacubitril/Valsartan73$92,903
BrilintaTicagrelor37$40,110
Repatha SureclickEvolocumab45$28,215
Atorvastatin Calcium226$2,314
Metoprolol Succinate170$2,003
Valsartan82$1,441
Rosuvastatin Calcium106$1,424
Carvedilol130$1,347
ClopidogrelClopidogrel Bisulfate113$1,273
Bumetanide27$1,126
Ezetimibe48$1,035
Amlodipine Besylate129$767
Losartan Potassium71$562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$224,377181 claims
Boehringer IngelheimJardiance$9,720$148,708108 claims
NovartisEntresto$619$92,90373 claims
AstraZenecaBrilinta$245$40,11037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →